Tuesday, October 20, 2026 · Five AI analysts screened this index for stocks with the best shot at gaining +5% within 30 days
Optimistic Normal choppiness · VIX 17.3
Many FTSE 100 constituents posted large single-day rallies alongside strong 5-day and 30-day returns, consistent with a broad earnings-season beat cycle concentrated in consumer staples, retail, healthcare, and travel names. Miners, banks, and asset managers are lagging sharply on commodity price and rate-sensitive pressure, creating a bifurcated tape where momentum leadership sits outside the traditional index heavyweights.
Which of today's picks to actually take, and at what size, given what you are already holding. Each pick's own Suggested Allocation sizes it in isolation; this table applies the portfolio limits — at most 20 open positions and 60% of the portfolio committed in total. Run with --capital 25000 to see these sizes as order amounts rather than percentages.
| Rank | Stock | Action | Size | Entry → Target | Notes |
|---|---|---|---|---|---|
| #1 | RKT.L | SKIP | — | £5,518.00 → £5,793.91 stop £5,159.33 |
Half-Kelly sizes this at 0% — the odds carry no edge worth capital. |
| #2 | IMB.L | SKIP | — | £2,844.00 → £2,986.20 stop £2,588.04 |
Half-Kelly sizes this at 0% — the odds carry no edge worth capital. |
| #3 | CPG.L | SKIP | — | £32.64 → £34.27 stop £29.44 |
Half-Kelly sizes this at 0% — the odds carry no edge worth capital. |
| #4 | AZN.L | SKIP | — | £12,618.00 → £13,248.90 stop £11,684.27 |
Half-Kelly sizes this at 0% — the odds carry no edge worth capital. |
Already open: LGEN.L (to Oct 21), SSE.L (to Oct 21), AAPL (to Oct 22), KGF.L (to Oct 23), DHR (to Oct 24), DCC.L (to Oct 25), DPLM.L (to Oct 28), ABDN.L (to Oct 30), EMR (to Nov 1), ALW.L (to Nov 1), PSN.L (to Nov 1), MSFT (to Nov 4) … and 62 more. Symbols you already hold were excluded from this run's candidates rather than re-picked.
Position-sizing guidance only — half-Kelly per pick, bounded by the limits above. Not personal investment advice.
Reckitt Benckiser makes well-known household and health brands like Dettol, Nurofen, and Durex. The stock has risen solidly and is beating the market, with technicals pointing to continued strength, though trading volume isn't fully backing up the price gains. The main risk is that this volume mismatch could signal the rally is more fragile than the price chart suggests.
Why the AI likes it
What could go wrong
Calibrated probability: 55% (raw model estimate: 63%) — adjusted using the accuracy of past resolved picks.
Trade math
Suggested allocation is half-Kelly sizing guidance capped at 10% — not personal investment advice. Allocations are scaled to 85% of half-Kelly for the current market regime.
What each AI analyst estimated
Imperial Brands sells cigarettes and other tobacco products around the world, generating steady cash flow that investors often favor in uncertain times. Its stock surged alongside other consumer-staples names on what appears to be a strong earnings reaction and is trading near its highest level of the past month. The main risks are the ongoing regulatory and legal pressures tobacco companies face, the chance that part of the one-day jump unwinds, and another earnings report landing inside the 30-day window.
Why the AI likes it
What could go wrong
Calibrated probability: 55% (raw model estimate: 61%) — adjusted using the accuracy of past resolved picks.
Trade math
Suggested allocation is half-Kelly sizing guidance capped at 10% — not personal investment advice. Allocations are scaled to 85% of half-Kelly for the current market regime.
What each AI analyst estimated
Compass Group is the world's largest contract catering and food-services company, serving businesses, schools, and hospitals globally. Its shares have been climbing steadily and beating the broader market, with healthy technical readings suggesting the move has further to go. The main risk is simply that any broad market pullback could reverse this kind of steady momentum trade.
Why the AI likes it
What could go wrong
Calibrated probability: 55% (raw model estimate: 66%) — adjusted using the accuracy of past resolved picks.
Trade math
Suggested allocation is half-Kelly sizing guidance capped at 10% — not personal investment advice. Allocations are scaled to 85% of half-Kelly for the current market regime.
What each AI analyst estimated
AstraZeneca is one of the world's largest pharmaceutical companies, developing treatments across oncology, respiratory, and other disease areas. Its shares have picked up solid 5-day momentum and modestly beaten the market, backed by rising trading volume. The biggest risk is that an earnings report lands just 10 days from now, which could move the stock sharply in either direction before the 30-day window closes.
Why the AI likes it
What could go wrong
Calibrated probability: 55% (raw model estimate: 63%) — adjusted using the accuracy of past resolved picks.
Trade math
Suggested allocation is half-Kelly sizing guidance capped at 10% — not personal investment advice. Allocations are scaled to 85% of half-Kelly for the current market regime.
What each AI analyst estimated
This report identifies stocks with an AI-assessed probability of gaining +5% within 30 calendar days (target exit by November 19, 2026). Picks are ranked by how many independent AI agents agreed — more agreement means higher conviction. The guide below tells you exactly how to act on them.
Step-by-Step Action Plan
Position Sizing by Conviction Tier
Size each position according to the coloured border on its pick card. Cap your total exposure across all picks from this report at 25% of your overall trading budget.
| Agents Agreeing | What It Means | Max Allocation Per Pick |
|---|---|---|
| 5/5 | Highest conviction — all five independent analytical checks passed | Up to 10% |
| 4/5 | Very high conviction — four of five independent checks aligned | Up to 8% |
| 3/5 | High conviction — three agents independently agreed | Up to 6% |
| 2/5 | Moderate conviction — two agents independently agreed | Up to 4% |
| 1 Agent | Speculative — solo pick, admitted only at Very High confidence | Up to 2% |
The Three Exit Rules
A plain-English guide to every figure shown on each pick card — what it means, how it is calculated, and what a good or bad value looks like.
Scout scanned 100 FTSE 100 constituents and short-listed 25 candidates for deep analysis by the five analysts. Here is what happened to each one.
Checks 30-day price history for every candidate before making any selection. Requires positive period return and positive 5-day momentum as mandatory gates. Ranks picks by proximity to their period high and adjusts probability based on volume. Uses news only to rule out major negative catalysts.
Searches earnings results, analyst upgrades, and revenue trends before checking price data. Requires at least one verifiable fundamental catalyst — earnings beat, analyst upgrade, or revenue acceleration — within the last 60 days. Favours stocks with strong fundamentals trading below recent highs (value entry).
Hunts for specific events within the last 21 days: FDA approvals, major contract wins, product launches, earnings surprises, or significant analyst upgrades. Requires a positive price reaction confirming the market is recognising the catalyst. Also scans for upcoming events that could drive further gains.
Maps the macroeconomic regime (risk-on / risk-off / neutral) and identifies sectors benefiting from current conditions before looking at individual stocks. Only selects stocks from macro-aligned sectors with confirmed sector tailwinds. Adjusts for interest rate sensitivity and geopolitical factors.
Reviews the final picks after all four analysts agree and actively challenges each bull thesis. Searches for bearish technical signals, negative news, insider selling, and elevated short interest that the agreeing agents may have underweighted. Produces evidence-based counter-arguments shown on each pick card.
Pure-quant analyst: no news, no narrative, only numbers. Identifies mean-reversion setups from RSI extremes (<35) with momentum turning, Bollinger squeeze breakouts, and multi-factor quant scores using RSI, MACD, OBV, short interest, and insider transaction data. Counterbalances narrative bias across the four analyst agents.